Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, March 17, 2015 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it submitted a supplemental new drug application for...
NORTHBROOK, Ill., March 6th, 2015, – Astellas today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of CRESEMBA®...
Tokyo, Feb. 2, 2015—Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced today that the company will now make trial data available through www.clinicalstudydatarequest.com, an...
Hershey, PA & Rockville, MD and Tokyo, Japan. January 30, 2015 – Immunomic Therapeutics, Inc. (“Immunomic Therapeutics”), a company developing next generation vaccines based on the LAMP-vax...
SAN FRANCISCO, CA and TOKYO, JAPAN – January 22, 2015 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 TERRAIN trial...
NORTHBROOK, Ill., January 22, 2015, – Astellas today announced that the U.S. Food and Drug Administration’s (FDA) Anti-infective Drugs Advisory Committee voted unanimously to recommend...
South San Francisco, CA, and Tokyo, December 23, 2014 – Cytokinetics, Incorporated (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas") announced today an amendment to...
SAN FRANCISCO, CA and TOKYO – December 12, 2014 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (Tokyo: 4503), announced today the presentation of Stage 1 and preliminary Stage 2...
TOKYO, JAPAN – December 10, 2014 – Astellas Pharma Inc. (Tokyo: 4503), announced today that Stage 1 and preliminary Stage 2 data from a Phase 2 study evaluating the use of enzalutamide as a...
Tokyo, Dec. 9, 2014 – Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced that it has been selected for the third year to be included in the...
TOKYO, Japan - December 2, 2014 - Astellas Pharma Inc. (TSE: 4503) (“Astellas”) announced that its license agreement with Janssen Biotech, Inc. (“Janssen”) to develop and commercialize...
Tokyo, December 2, 2014 –Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that the European Commission (EC) has granted a variation to amend the Marketing Authorisation for...
The additional sub-group analyses of C-OPERA in findings regarding the inhibition of joint structural destruction were reported at the American College of Rheumatology/Association of Rheumatology...
Follow us
